Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Merck
Fuji
Cantor Fitzgerald
Johnson and Johnson
McKinsey
Mallinckrodt
QuintilesIMS
Argus Health

Generated: November 16, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 090374

« Back to Dashboard

NDA 090374 describes ZALEPLON, which is a drug marketed by Aurobindo Pharma, Cipla Ltd, Hikma Pharms, Mylan, Orchid Hlthcare, Teva Pharms, Unichem, Upsher-smith Labs, and West-ward Pharms Int, and is included in ten NDAs. It is available from nineteen suppliers. Additional details are available on the ZALEPLON profile page.

The generic ingredient in ZALEPLON is zaleplon. There are twelve drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the zaleplon profile page.
Summary for 090374
Tradename:ZALEPLON
Applicant:Orchid Hlthcare
Ingredient:zaleplon
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 090374
Mechanism of ActionGABA A Agonists
Physiological EffectCentral Nervous System Depression
Suppliers and Packaging for NDA: 090374
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ZALEPLON zaleplon CAPSULE;ORAL 090374 ANDA OrchidPharma Inc 42043-210 42043-210-01 100 CAPSULE in 1 BOTTLE (42043-210-01)
ZALEPLON zaleplon CAPSULE;ORAL 090374 ANDA OrchidPharma Inc 42043-211 42043-211-01 100 CAPSULE in 1 BOTTLE (42043-211-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength5MG
Approval Date:Sep 17, 2009TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength10MG
Approval Date:Sep 17, 2009TE:ABRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Express Scripts
Baxter
Covington
Argus Health
Medtronic
Cerilliant
Federal Trade Commission
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.